Form 4: Ocuphire Pharma Director Sean Ainsworth Receives Stock Options and Restricted Stock Units

Director Sean Ainsworth receives stock options and restricted stock units in Ocuphire Pharma, Inc.

Summary

• Sean Ainsworth, a director of Ocuphire Pharma, Inc., received 41,143 restricted stock units and an option to purchase 35,181 shares of common stock on June 11, 2024.
• The restricted stock units vest upon the earlier of the one-year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service.
• The stock options have an exercise price of $1.72 and also vest upon the earlier of the one-year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service, and expire on June 10, 2034.
• Following these transactions, Ainsworth directly owns 88,358 shares of Ocuphire Pharma common stock and options to purchase 35,181 shares.
• Amy Rabourn, acting as attorney-in-fact, signed the Form 4 on behalf of Sean Ainsworth on June 13, 2024, utilizing a power of attorney dated February 1, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options and restricted stock units is a standard practice and suggests confidence in the company's future performance. There are no explicitly negative indicators.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule, tied to continued service, incentivizes the director to remain with the company.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the stock options and restricted stock units is contingent on the director's continued service.

Industry Context

This is a standard SEC filing related to insider transactions. Grants of stock options and restricted stock units are common forms of executive compensation in the pharmaceutical industry.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry, often used to align management's interests with shareholder value.
• Companies like Alnylam Pharmaceuticals and BioMarin Pharmaceutical also utilize stock options and restricted stock units as part of their compensation strategy for directors and officers.
• The vesting schedules, typically ranging from one to four years, are designed to incentivize long-term commitment and performance.

Stakeholder Impact

• The grant of equity to a director can align their interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates